Pancreatic cancer kills roughly 80% of patients within a year of diagnosis. For those whose tumors have already spread and who have failed first-line chemotherapy, the options narrow to treatments that historically buy a median of about six months. On June 1, 2026, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, researchers presented full Phase 3 results showing that a once-daily oral pill called daraxonrasib nearly doubled overall survival in exactly that patient population.
The data, drawn from the RASolute 302 trial, represent the first time a targeted therapy has demonstrated this magnitude of survival benefit in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). And the FDA has already acted: within 48 hours of receiving a request from the drug’s developer, Revolution Medicines, the agency cleared daraxonrasib for expanded access, letting patients outside the trial begin receiving it immediately.
Why pancreatic cancer has been so hard to treat
Roughly 90% to 95% of pancreatic cancers are driven by mutations in the KRAS gene, part of the broader RAS protein family. For decades, oncologists called RAS “undruggable.” The protein’s surface is smooth and featureless, offering few places for a drug molecule to grab hold, and it binds so tightly to the signaling molecule GTP that blocking the interaction seemed impossible.
That left chemotherapy as the backbone of treatment. In the second-line setting, after a standard regimen like FOLFIRINOX or gemcitabine-based therapy has failed, the most commonly used option has been nanoliposomal irinotecan combined with fluorouracil and leucovorin. That combination, approved in 2015, extended median survival to about 6.1 months in its pivotal trial. Progress since then has been incremental at best.
Daraxonrasib, also known by its research code RMC-6236, takes a fundamentally different approach. Rather than targeting a single RAS mutation, it inhibits multiple forms of the RAS protein simultaneously, a strategy known as pan-RAS inhibition. A review published in Nature Reviews Clinical Oncology describes this mechanism as a meaningful departure from both conventional chemotherapy and the mutation-specific RAS inhibitors (like sotorasib and adagrasib) that have shown activity in lung cancer but target only the KRAS G12C variant, which is rare in pancreatic tumors.
What the RASolute 302 trial showed
RASolute 302 is a randomized Phase 3 trial that enrolled patients with previously treated metastatic PDAC and compared daraxonrasib, given as a single daily oral dose, against the investigator’s choice of standard therapy. The trial’s primary endpoint was overall survival.
The results presented at ASCO showed that patients randomized to daraxonrasib lived nearly twice as long as those on the control arm. While the full manuscript with detailed survival curves, hazard ratios, confidence intervals, and subgroup breakdowns has not yet been published in a peer-reviewed journal, the magnitude of the benefit was large enough to prompt immediate regulatory action and drew a standing-room-only audience at the ASCO plenary session.
For context, a near-doubling of overall survival in second-line metastatic pancreatic cancer is virtually unprecedented. Most positive trials in this space have measured gains in weeks, not months. The oncology community’s response at ASCO reflected that: this was not a marginal improvement on a statistical table. It was a shift in what clinicians believed was possible in a disease long defined by futility.
The FDA moved in 48 hours
The regulatory timeline around daraxonrasib has been unusually fast, even by the standards of expedited oncology programs. According to an FDA press announcement, Revolution Medicines submitted its expanded access request on April 28, 2026. The agency issued a “safe to proceed” letter on April 30, just two days later.
That speed did not come out of nowhere. The FDA had already granted daraxonrasib two significant designations before the expanded access decision:
- Breakthrough Therapy designation, reserved for drugs that show substantial improvement over existing treatments for serious or life-threatening conditions. This designation gives the sponsor access to intensive FDA guidance and rolling review.
- Orphan Drug designation, which applies to drugs targeting diseases affecting fewer than 200,000 people in the United States. Pancreatic cancer, despite being the third-leading cause of cancer death in the U.S., qualifies because of its relatively low prevalence at any given time.
Both designations meant the FDA had already been reviewing daraxonrasib’s safety data through ongoing interactions with Revolution Medicines. By the time the expanded access request arrived, agency reviewers were not starting from scratch. They had accumulated enough familiarity with the drug’s risk profile to move quickly.
For patients who had run out of approved options, that 48-hour window was not an abstraction. It meant access to a drug with a demonstrated survival benefit in a controlled trial, available before any formal approval decision.
What the data do not yet tell us
The ASCO presentation delivered the topline survival signal, but several important questions remain unanswered until the full trial data are published.
Exact survival figures. The precise median overall survival in each arm, the hazard ratio, and the confidence intervals have been presented at the meeting but are not yet available in the ClinicalTrials.gov registry or in a peer-reviewed manuscript. Those numbers will determine whether “nearly doubled” means an improvement from six months to eleven, or from six to ten, or some other combination. The distinction matters for clinical decision-making.
Safety details. The FDA’s expanded access clearance confirms the agency considers daraxonrasib safe enough to administer outside a trial setting, but the specific adverse event profile under expanded access has not been publicly detailed. Whether the expanded access protocol uses the same dose and the same patient selection criteria as the Phase 3 trial is not specified. Real-world toxicity can differ from trial toxicity, particularly if sicker patients with poorer performance status gain access.
Subgroup performance. Pancreatic cancers carry different KRAS mutation variants (G12D, G12V, G12R, and others). Whether daraxonrasib’s benefit is consistent across these subtypes, or concentrated in one, will shape how oncologists select patients for treatment. Subgroup data from the ASCO presentation will need to be confirmed in the full publication.
Path to full approval. No public document confirms whether Revolution Medicines has filed or plans to file a new drug application based on the RASolute 302 results. Breakthrough Therapy designation entitles the company to rolling submission, which could significantly shorten the review timeline. But whether that process has begun, or whether the company will wait for longer follow-up data, remains unclear.
Durability and resistance. RAS-targeted therapies in other tumor types have faced resistance mechanisms that limit how long responses last. Whether daraxonrasib will encounter similar challenges in pancreatic cancer, and whether combination strategies might extend its benefit, are open scientific questions that the current data do not address.
What this means for patients and oncologists right now
The convergence of a strong Phase 3 survival signal, rapid FDA expanded access, and two prior expedited designations places daraxonrasib in rare territory for pancreatic cancer therapeutics. For patients with previously treated metastatic PDAC, the practical implications are immediate: expanded access is open, and the drug can be administered as a single daily pill rather than an intravenous infusion, which has meaningful quality-of-life implications for people who are already sick.
For oncologists, the RASolute 302 results challenge a long-standing assumption that targeted therapy could not meaningfully move the needle in PDAC. Pan-RAS inhibition has gone from a theoretical concept to a strategy backed by Phase 3 evidence in a matter of years, a pace that reflects both the urgency of the disease and advances in drug design that finally cracked the RAS problem.
The full picture will sharpen as the detailed trial data move from the ASCO stage into peer-reviewed journals and updated registry entries. Until then, the evidence supports a clear conclusion: in a cancer where survival gains have historically been measured in weeks, daraxonrasib has delivered something that looks like months. The complete data, when published, will determine exactly how many.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
